Back to top
more

Cresco Labs Inc. (CRLBF)

(Delayed Data from OTC)

$0.69 USD

0.69
949,742

-0.02 (-2.17%)

Updated Aug 6, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of -3.39% and -2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +7.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?

by Sundeep Ganoria

Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.

Sundeep Ganoria headshot

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

by Sundeep Ganoria

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Sundeep Ganoria headshot

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of 0% and 0.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AdaptHealth Corp. (AHCO) Meets Q1 Earnings Estimates

by Zacks Equity Research

AdaptHealth (AHCO) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 0% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -100% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -13.33% and 0.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Universal Health Services (UHS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Universal Health Services (UHS) delivered earnings and revenue surprises of 27.89% and 1.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 2.33% and 1.96%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates

by Zacks Equity Research

AdaptHealth (AHCO) delivered earnings and revenue surprises of -66.67% and 2.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings

by Zacks Equity Research

Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.

Zacks Equity Research

Investors Heavily Search Cresco Labs Inc. (CRLBF): Here is What You Need to Know

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) concluded the recent trading session at $2, signifying no movement from its prior day's close.

Zacks Equity Research

Brokers Suggest Investing in Cresco Labs Inc. (CRLBF): Read This Before Placing a Bet

by Zacks Equity Research

The average brokerage recommendation (ABR) for Cresco Labs Inc. (CRLBF) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Is Cresco Labs Inc. (CRLBF) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cresco Labs Inc. (CRLBF) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) closed the most recent trading day at $2.29, moving -0.43% from the previous trading session.

Zacks Equity Research

Despite Fast-paced Momentum, Cresco Labs Inc. (CRLBF) Is Still a Bargain Stock

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 150% and 3.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?